StreetInsider.com News Articles

Compass Therapeutics publishes Phase 2/3 biliary cancer trial results

Sat, 24 Oct 2026 04:15:20 -0400

Compass Therapeutics, Inc. (NASDAQ: CMPX) announced the publication of results from its Phase 2/3 COMPANION-002 study of tovecimig in the Journal of Clinical Oncology on Oct. 24, 2026. The results were also presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.

The randomized study evaluated tovecimig combined with paclitaxel versus paclitaxel alone in 168 patients with previously treated, advanced biliary tract cancer (BTC). The trial met its primary endpoint, with the combination showing an objective response rate (ORR) of 18.0% compared with 5.3% for paclitaxel alone (p=0.0228). The study also met its key secondary endpoint of

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

Sat, 24 Oct 2026 04:15:00 -0400

As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of disease progression or death.
Responses were durable, with a median duration of response (DOR) of 4.9 months, and disease control rate (DCR) was also significantly improved (62.2% vs. 36.8%).
A new, post hoc analysis of overall survival (OS) included in the JCO publication uses the Two-Stage Estimation, an established method for adjusting for crossover, and demonstrates an OS hazard ratio of 0.85 (95% CI, 0.59–1.26; p=0.53).
Safety profile

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

Sat, 24 Oct 2026 04:15:00 -0400

As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of disease progression or death.
Responses were durable, with a median duration of response (DOR) of 4.9 months, and disease control rate (DCR) was also significantly improved (62.2% vs. 36.8%).
A new, post hoc analysis of overall survival (OS) included in the JCO publication uses the Two-Stage Estimation, an established method for adjusting for crossover, and demonstrates an OS hazard ratio of 0.85 (95% CI, 0.59–1.26; p=0.53).
Safety profile

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 14 Oct 2026 16:30:00 -0400

BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grant consists of non-qualified stock options to purchase 200,000 shares of common stock at an exercise price of $0.86 per share, which is equal to the closing price of the Company’s common stock on October 13, 2026. The

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 14 Oct 2026 16:30:00 -0400

BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grant consists of non-qualified stock options to purchase 200,000 shares of common stock at an exercise price of $0.86 per share, which is equal to the closing price of the Company’s common stock on October 13, 2026. The

Form 4 Compass Therapeutics, For: Oct 01 Filed by: Lerner Neil

Fri, 02 Oct 2026 08:00:00 -0400
si-local-file:///var/storage/secattach/20261002/27139004.html

Form 4 Compass Therapeutics, For: Sep 24 Filed by: Lerner Neil

Fri, 25 Sep 2026 08:01:00 -0400
si-local-file:///var/storage/secattach/20260925/27104298.html

Compass Therapeutics (CMPX) Reiterated at Overweight by Cantor Fitzgerald

Wed, 23 Sep 2026 06:58:34 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Compass Therapeutics (NASDAQ: CMPX).
The analyst commented, "This morning (9/22), the FDA recommended that Compass conduct an additional trial demonstrating a survival benefit before submitting a BLA for tovecimig in 2L BTC. This was our worst-case scenario and surprising given COMPANION-002 met its ORR primary endpoint, demonstrated a significant PFS benefit, and had OS confounded by substantial cross-over."
For an analyst ratings summary and ratings history on Compass Therapeutics click here. For more ratings news on Compass Therapeutics click here.
Shares of Compass Therapeutics closed at $1.24 yesterday.

Compass Therapeutics (CMPX) PT Lowered to $12 at H.C. Wainwright

Wed, 23 Sep 2026 06:57:21 -0400
(Updated - September 23, 2026 6:57 AM EDT)
H.C. Wainwright analyst Joseph Pantginis lowered the price target on Compass Therapeutics (NASDAQ: CMPX) to $12.00 (from $24.00) while maintaining a Buy rating.
The analyst commented: 'Yesterday, Compass disclosed that FDA has recommended it conduct a trial demonstrating a survival benefit before proceeding with a BLA for tovecimig in previously treated, advanced BTC. We remind investors, the FDA's suggestion comes based off a pivotal study that met its primary endpoint on ORR (18.0% vs. 5.3%, p=0.0228) and delivered a highly significant PFS benefit (median 4.7 vs. 2.6 months, HR 0.44, p<0.0001), but in which

Compass Therapeutics (CMPX) PT Lowered to $12 at H.C. Wainwright

Wed, 23 Sep 2026 06:57:21 -0400
(Updated - September 23, 2026 6:57 AM EDT)
H.C. Wainwright analyst Joseph Pantginis lowered the price target on Compass Therapeutics (NASDAQ: CMPX) to $12.00 (from $24.00) while maintaining a Buy rating.
The analyst commented: 'Yesterday, Compass disclosed that FDA has recommended it conduct a trial demonstrating a survival benefit before proceeding with a BLA for tovecimig in previously treated, advanced BTC. We remind investors, the FDA's suggestion comes based off a pivotal study that met its primary endpoint on ORR (18.0% vs. 5.3%, p=0.0228) and delivered a highly significant PFS benefit (median 4.7 vs. 2.6 months, HR 0.44, p<0.0001), but in which

Compass Therapeutics (CMPX) PT Lowered to $4 at Guggenheim

Wed, 23 Sep 2026 06:45:11 -0400
(Updated - September 23, 2026 6:45 AM EDT)
Guggenheim analyst Michael Schmidt lowered the price target on Compass Therapeutics (NASDAQ: CMPX) to $4.00 (from $8.00) while maintaining a Buy rating.
The analyst commented: "CMPX announced that the FDA recommended that CMPX conduct a trial to demonstrate a survival (OS) benefit prior to submitting a BLA for tovecimig. This is disappointing news. Recall, CMPX previously reported that its Phase 2/3 randomized trial COMPANION-002, evaluating tovecimig (DLL4 x VEGF-A bsAb) + paclitaxel vs. paclitaxel in patients with advanced biliary tract cancer (BTC), had met its primary endpoint of improving ORR. The secondary endpoint of

Compass Therapeutics (CMPX) PT Lowered to $4 at Guggenheim

Wed, 23 Sep 2026 06:45:11 -0400
(Updated - September 23, 2026 6:45 AM EDT)
Guggenheim analyst Michael Schmidt lowered the price target on Compass Therapeutics (NASDAQ: CMPX) to $4.00 (from $8.00) while maintaining a Buy rating.
The analyst commented: "CMPX announced that the FDA recommended that CMPX conduct a trial to demonstrate a survival (OS) benefit prior to submitting a BLA for tovecimig. This is disappointing news. Recall, CMPX previously reported that its Phase 2/3 randomized trial COMPANION-002, evaluating tovecimig (DLL4 x VEGF-A bsAb) + paclitaxel vs. paclitaxel in patients with advanced biliary tract cancer (BTC), had met its primary endpoint of improving ORR. The secondary endpoint of

Compass Therapeutics (CMPX) PT Lowered to $4 at Citizens After FDA Dialogue

Wed, 23 Sep 2026 04:31:17 -0400

Citizens analyst Reni Benjamin lowered the price target on Compass Therapeutics (NASDAQ: CMPX) to $4.00 (from $10.00) while maintaining a Market Outperform rating.
The analyst commented, "We reiterate our Market Outperform rating for Compass Therapeutics but lower our price target to $4 (from $10) based on a platform and cash/share analysis. Yesterday, Compass announced the outcome of a written regulatory dialogue with the FDA, during which the agency requested an additional trial to demonstrate an OS benefit in 2L+ BTC patients. Given the significant unmet need in BTC, we view the company’s decision to continue engaging with the FDA as the

Compass Therapeutics (CMPX) PT Lowered to $4 at Citizens After FDA Dialogue

Wed, 23 Sep 2026 04:31:17 -0400

Citizens analyst Reni Benjamin lowered the price target on Compass Therapeutics (NASDAQ: CMPX) to $4.00 (from $10.00) while maintaining a Market Outperform rating.
The analyst commented, "We reiterate our Market Outperform rating for Compass Therapeutics but lower our price target to $4 (from $10) based on a platform and cash/share analysis. Yesterday, Compass announced the outcome of a written regulatory dialogue with the FDA, during which the agency requested an additional trial to demonstrate an OS benefit in 2L+ BTC patients. Given the significant unmet need in BTC, we view the company’s decision to continue engaging with the FDA as the

Wedbush Downgrades Compass Therapeutics (CMPX) to Neutral

Tue, 22 Sep 2026 16:09:07 -0400
(Updated - September 22, 2026 4:09 PM EDT)
Wedbush analyst Robert Driscoll downgraded Compass Therapeutics (NASDAQ: CMPX) from Outperform to Neutral with a price target of $1.00.
The analyst comments "CMPX announced that the FDA has recommended the company conduct a trial demonstrating a survival benefit prior to proceeding with a BLA submission for tovecimig in previously treated, advanced BTC. CMPX continues to expect to submit a BLA in Q1:27 while continuing to gain additional feedback from the FDA, but does not believe a new trial is warranted based on clinical data from the COMAPANION-002 study. As a reminder, COMPANION-002 demonstrated a

Wedbush Downgrades Compass Therapeutics (CMPX) to Neutral

Tue, 22 Sep 2026 16:09:07 -0400
(Updated - September 22, 2026 4:09 PM EDT)
Wedbush analyst Robert Driscoll downgraded Compass Therapeutics (NASDAQ: CMPX) from Outperform to Neutral with a price target of $1.00.
The analyst comments "CMPX announced that the FDA has recommended the company conduct a trial demonstrating a survival benefit prior to proceeding with a BLA submission for tovecimig in previously treated, advanced BTC. CMPX continues to expect to submit a BLA in Q1:27 while continuing to gain additional feedback from the FDA, but does not believe a new trial is warranted based on clinical data from the COMAPANION-002 study. As a reminder, COMPANION-002 demonstrated a

Compass Therapeutics (CMPX) PT Lowered to $8 at Craig-Hallum

Tue, 22 Sep 2026 10:56:34 -0400

Craig-Hallum analyst Albert Lowe lowered the price target on Compass Therapeutics (NASDAQ: CMPX) to $8.00 (from $15.00) while maintaining a Buy rating.

Stifel Reiterates Buy Rating on Compass Therapeutics (CMPX)

Tue, 22 Sep 2026 10:22:00 -0400

Stifel analyst Stephen Willey reiterated a Buy rating and $6.00 price target on Compass Therapeutics (NASDAQ: CMPX).
The analyst comments "We’ve maintained (incorrectly) a positive bias on regulatory feedback re: tovecimig full approval prospects given 1) the clearly confounding effect of patient crossover on COMPANION-002 survival data; 2) the absence of any FDA-approved therapies in 2L BTC; and 3) KOL feedback suggesting a drug reducing risk of disease progression by >50% and improving crossover-agnostic survival by ~3 months gets used in all 2L BTC patients lacking actionable genomic alterations. Management is interpreting FDA’s feedback to be specific to full approval and

FDA tells Compass Therapeutics to run survival trial before BLA

Tue, 22 Sep 2026 08:30:52 -0400

Compass Therapeutics, Inc. (Nasdaq: CMPX) disclosed that the U.S. Food and Drug Administration has recommended the company conduct a trial demonstrating a survival benefit before submitting a Biologics License Application (BLA) for tovecimig in patients with previously treated, advanced biliary tract cancer (BTC).

Compass said it disagrees with the FDA's recommendation, stating it does not believe a new trial is warranted given data from its Phase 2/3 COMPANION-002 study and the unmet medical need for BTC patients. The company said it intends to continue engaging with the FDA as it prepares a BLA submission.

In the COMPANION-002 study, tovecimig combined with paclitaxel

Form 8-K Compass Therapeutics, For: Sep 22

Tue, 22 Sep 2026 08:30:00 -0400
si-local-file:///var/storage/secattach/20260922/27088191.html

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

Tue, 22 Sep 2026 08:30:00 -0400

The FDA recommended that Compass conduct a trial to demonstrate a survival benefit prior to submitting a BLA for tovecimig.
Compass does not believe that a new trial is warranted prior to submitting a BLA based on the data from the Phase 2/3 COMPANION-002 study and the urgent unmet medical need for patients with BTC.
Compass intends to further engage with the FDA as we continue to prepare a BLA submission for tovecimig.
Compass remains confident in tovecimig based on the positive results from COMPANION-002, including the statistically significant improvements in ORR and PFS.

BOSTON, Sept. 22, 2026

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

Tue, 22 Sep 2026 08:30:00 -0400

The FDA recommended that Compass conduct a trial to demonstrate a survival benefit prior to submitting a BLA for tovecimig.
Compass does not believe that a new trial is warranted prior to submitting a BLA based on the data from the Phase 2/3 COMPANION-002 study and the urgent unmet medical need for patients with BTC.
Compass intends to further engage with the FDA as we continue to prepare a BLA submission for tovecimig.
Compass remains confident in tovecimig based on the positive results from COMPANION-002, including the statistically significant improvements in ORR and PFS.

BOSTON, Sept. 22, 2026

Form SCHEDULE 13G/A Compass Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.

Fri, 14 Aug 2026 16:00:00 -0400
si-local-file:///var/storage/secattach/20260814/26929784.html

Form SCHEDULE 13G/A Compass Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.

Fri, 14 Aug 2026 16:00:00 -0400
si-local-file:///var/storage/secattach/20260814/26929784.html

Form SCHEDULE 13G Compass Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 09:13:00 -0400
si-local-file:///var/storage/secattach/20260807/26888396.html